Valuation: Glenmark Pharmaceuticals Limited

Market Cap 654B 6.84B 5.91B 5.55B 5.05B 9.49B 9.65B 65.07B 25.44B 328B 25.69B 25.13B 1,089B P/E 2026
44.2x
P/E 2027 * 28.2x
Enterprise Value 615B 6.43B 5.55B 5.22B 4.75B 8.92B 9.07B 61.16B 23.91B 308B 24.15B 23.62B 1,023B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.81x
Free-Float
51.04%
Yield 2026
0.12%
Yield 2027 * 0.16%
1 day-0.07%
1 week+2.13%
Current month+3.78%
1 month+0.74%
3 months+1.79%
6 months+16.06%
Current year+13.92%
1 week 2,245
Extreme 2245
2,341.6
1 month 2,162
Extreme 2162
2,341.6
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 722.1
Extreme 722.1
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2000
Director of Finance/CFO 54 27/05/2025
President - 15/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 12/05/2011
Director/Board Member 85 14/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+2.13%+14.25%+189.31% 6.86B
-0.10%-1.08%+17.70%+70.44% 48.57B
-3.26%-1.15%+50.36%+115.32% 40.99B
-0.60%-1.83%-7.11%+15.98% 12.35B
-2.75%+2.45%+14.83%+74.39% 12.2B
-0.19%-0.19%+29.10%+135.91% 9.08B
+1.56%+5.52%+23.46%+39.78% 7.41B
+0.52%+3.93%+39.82%-13.06% 7.13B
-2.51%+3.10%-27.59%+27.09% 5.92B
+1.61%+5.83%+37.47%+112.80% 4.73B
Average -0.58%+1.77%+19.23%+76.80% 15.52B
Weighted average by Cap. -1.12%+1.13%+24.80%+81.70%

Financials

2026 2027 *
Net sales 153B 1.6B 1.38B 1.3B 1.18B 2.22B 2.26B 15.23B 5.95B 76.67B 6.01B 5.88B 255B 168B 1.76B 1.52B 1.43B 1.3B 2.44B 2.48B 16.7B 6.53B 84.09B 6.59B 6.45B 279B
Net income 20.53B 215M 185M 174M 158M 298M 303M 2.04B 798M 10.28B 806M 789M 34.17B 23.11B 242M 209M 196M 178M 335M 341M 2.3B 899M 11.57B 907M 888M 38.46B
Net Debt -39.29B -411M -355M -334M -303M -570M -580M -3.91B -1.53B -19.68B -1.54B -1.51B -65.39B -14.47B -151M -131M -123M -112M -210M -214M -1.44B -563M -7.25B -568M -556M -24.09B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
14/08/26 INR 2,318.40 -0.07% 629,081
13/08/26 INR 2,320.00 +1.31% 413,167
12/08/26 INR 2,290.00 +0.62% 464,575
11/08/26 INR 2,276.00 +1.10% 284,670
10/08/26 INR 2,251.30 -1.22% 257,787
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,318.40INR
Average target price
2,497.73INR
Spread / Average Target
+7.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock